Allergan antes up $90M in a landmark CRISPR/Cas9 collaboration with Editas on eye diseases
Allergan is jumping into the CRISPR business.
The biotech struck a deal to partner with CRISPR/Cas9 leader Editas $EDIT on up to five programs aimed …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
